Palleon Pharmaceuticals
PrivateLast Round
Series B
Sep 17, 2020
Est. Valuation
$238.83M
Total Funding Raised
$147.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Palleon Pharmaceuticals operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Series B round in September 2020.
Palleon Pharmaceuticals is a biotechnology company that develops glyco-immunology therapeutics to treat cancer and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Palleon Pharmaceuticals Comparables
Compare Palleon Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OncoC4, Inc. | 81% | |
| Valora Therapeutics Inc. | 79% | |
| Tacalyx | 77% |
For institutional investors. Book with your work email.
Palleon Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 17, 2020 | ||||
| Series A | Oct 4, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Palleon Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series B |
| Vertex Ventures HC | Series A, Series B |
| AbbVie Ventures | Series A, Series B |
| Citadel | Series B |
| Matrix Capital Management | Series B |
| Pfizer Ventures | Series B, Series A |
| Takeda Ventures | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 79% MoM, reaching 5K.
- Apr 20, 2026
Presented B7-H3 Targeted Sialidase at the 2026 AACR Annual Meeting.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 11, 2026
Palleon Pharmaceuticals Inc. presents Phase 2 results for HLX79/E-602 in primary membranous nephropathy at ACR Convergence 2026 in Florida on Nov 11th '26.
- is_developingOct 23, 2026
Palleon Pharmaceuticals Inc. is a clinical-stage biotechnology company developing glycan editing, a new approach to immune modulation in autoimmune disease and cancer.
- attends_eventOct 23, 2026
Palleon Pharmaceuticals Inc. presents Phase 2 results for HLX79/E-602 in primary membranous nephropathy at ASN Kidney Week 2026 in Colorado on Oct 23rd '26.
- attends_eventOct 16, 2026
Palleon Pharmaceuticals Inc. is scheduled to deliver an oral presentation on interim Phase 2 data for HLX79/E-602 in membranous nephropathy at the 2026 American College of Rheumatology (ACR) Convergence in Florida on Nov 11th '26.
For institutional investors. Book with your work email.
Palleon Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Palleon Pharmaceuticals's valuation, stock price, and market status.
Is Palleon Pharmaceuticals a public or private company?
Palleon Pharmaceuticals is a private company.
What is the current stock price of Palleon Pharmaceuticals?
Palleon Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Palleon Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Palleon Pharmaceuticals worth (valuation)?
Palleon Pharmaceuticals's valuation is estimated at $238.8M based on funding round data.
Can I buy Palleon Pharmaceuticals stock?
Palleon Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Palleon Pharmaceuticals's last funding round?
Palleon Pharmaceuticals's most recent funding round was Series B on September 17, 2020.
Who are the main investors in Palleon Pharmaceuticals?
Key investors in Palleon Pharmaceuticals include Matrix Capital Management, Pfizer Ventures, SR One.
Will Palleon Pharmaceuticals IPO soon?
No public IPO plans have been announced for Palleon Pharmaceuticals.
How can I track Palleon Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Palleon Pharmaceuticals's shares on secondary markets.